
The notice of this shareholders’ meeting serving as convening notice published today, in the French Bulletin des Annonces Légales Obligatoires (“BALO”) includes the agenda, the proposed resolutions as well as instructions to participate and vote for this meeting. This notice is also available on the company’s website: http://www.adocia.fr/WP/investors-welcome/shareholders-meeting.

All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be available on the company’s website from May 31, 2016.

Precisions regarding the AGM:

Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to participate in the AGM.

Shareholders holding bearer shares (“actions au porteur”) will need to obtain an certificate of shareholding (“attestation de participation”) from their brokers. This “attestation de participation” must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The “attestation de participation” may replace the admission card for shareholders wishing to attend the AGM in person.

Written questions from shareholders must be received at the latest four business days prior to the AGM by registered letter, addressed to the registered office, or by e-mail to contactinvestisseur@adocia.com.

Shareholders may obtain the legal documentation in preparation of the AGM as described in the article R.225-83 of the French Commercial Code by sending a request:

- By regular mail to: Adocia - Service Relations Investisseurs – 115 avenue Lacassagne, 69003 Lyon, or
- By e-mail to: contactinvestisseur@adocia.com.
About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.

Adocia’s extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

Adocia aims to deliver “Innovative medicine for everyone, everywhere.”

To learn more about Adocia, please visit us at www.adocia.com

For more information please contact:

<table>
<thead>
<tr>
<th>Adocia</th>
<th>Adocia Press Relations France</th>
<th>Adocia Press Relations Europe</th>
</tr>
</thead>
</table>
| Gérard Soula  
Chairman and CEO  
contactinvestisseurs@adocia.com  
Tél. : +33 4 72 610 610 | ALIZE RP  
Caroline Carmagnol et Florence Portejoie  
caroline@alizerp.com  
adocia@alizerp.com  
Tél. : +33 1 44 54 36 61 | MC Services AG  
Raimund Gabriel  
raimund.gabriel@mc-services.eu  
adocia@mc-services.eu  
Tél. : +49 89 210 228 0 |